Incyte Corporation (NASDAQ:INCY) Director Bros. Advisors Lp Baker bought 100,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were acquired at an average price of $132.00 per share, with a total value of $13,200,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Incyte Corporation (NASDAQ:INCY) traded down 3.63% during mid-day trading on Friday, reaching $129.46. 3,151,943 shares of the company traded hands. The stock’s 50-day moving average is $129.39 and its 200-day moving average is $130.36. Incyte Corporation has a 52 week low of $77.58 and a 52 week high of $153.15. The company’s market capitalization is $26.63 billion.

Incyte Corporation (NASDAQ:INCY) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The business had revenue of $326.40 million for the quarter, compared to analysts’ expectations of $318.45 million. During the same quarter last year, the business posted $0.18 earnings per share. The business’s revenue was up 32.5% compared to the same quarter last year. On average, equities analysts predict that Incyte Corporation will post ($0.86) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/08/bros-advisors-lp-baker-purchases-100000-shares-of-incyte-corporation-incy-stock.html.

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC purchased a new position in Incyte Corporation during the 1st quarter valued at about $105,000. D. Scott Neal Inc. purchased a new position in Incyte Corporation during the 2nd quarter valued at about $103,000. Cornerstone Advisors Inc. increased its holdings in Incyte Corporation by 19.6% during the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 145 shares in the last quarter. FNY Partners Fund LP increased its holdings in Incyte Corporation by 4,825.0% during the 1st quarter. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company’s stock valued at $131,000 after acquiring an additional 965 shares in the last quarter. Finally, Exane Asset Management purchased a new position in Incyte Corporation during the 2nd quarter valued at about $126,000. Hedge funds and other institutional investors own 91.06% of the company’s stock.

A number of research analysts recently issued reports on the stock. Oppenheimer Holdings Inc. set a $125.00 target price on shares of Incyte Corporation and gave the company a “hold” rating in a research report on Thursday, May 18th. Jefferies Group LLC restated a “buy” rating and set a $148.00 target price on shares of Incyte Corporation in a research report on Thursday, July 27th. J P Morgan Chase & Co set a $149.00 target price on shares of Incyte Corporation and gave the company a “buy” rating in a research report on Thursday, May 18th. BMO Capital Markets restated an “outperform” rating and set a $166.00 target price (up from $155.00) on shares of Incyte Corporation in a research report on Monday, June 5th. Finally, Credit Suisse Group set a $152.00 target price on shares of Incyte Corporation and gave the company a “buy” rating in a research report on Sunday, July 16th. Eight analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $140.16.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.